A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT04516096
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class
Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG:
AMX0035
Sponsor
Amylyx Pharmaceuticals Inc.